Development of gallium compounds for treatment of lymphoma: Gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 3, 2007, Pages 1228-1236

  Chitambar, Christopher R ^a   Purpi, David P ^a   Woodliff, Jeffrey ^a   Yang, Meiying ^a   Wereley, Janine P ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CASPASE 3; GALLIUM MALTOLATE; GALLIUM NITRATE; HYDROXYPYRONE GALLIUM; MITOQUINONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 42; MONOCLONAL ANTIBODY 6; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG UPTAKE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOMA; MITOCHONDRION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG EVALUATION; DRUG RESISTANCE, NEOPLASM; GALLIUM; HUMANS; LYMPHOMA; ORGANOMETALLIC COMPOUNDS; PYRONES; RECEPTORS, TRANSFERRIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34548075249     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.126342     Document Type: Article

References (40)

1. Bernhardt PV, Mattsson J, and Richardson DR (2006) Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. Inorg Chem 45:752-760.
2. Bernstein LR, Tanner T, Godfrey C, and Noll B (2000) Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability. Metal Based Drugs 7:33-47.
3. Chitambar CR (2004) Gallium nitrate for the treatment of non-Hodgkin's lymphoma. Expert Opin Invest Drugs 13:531-541.
4. Chitambar CR, Boon P, and Wereley JP (1996) Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate. Clin Cancer Res 2:1009-1015.
5. Chitambar CR, Matthaeus WG, Antholine WE, Graff K, and O'Brien WJ (1988) Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 72:1930-1936.
6. Chitambar CR, Narasimhan J, Guy J, Sem DS, and O'Brien WJ (1991) Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res 51:6199-6201.
7. Chitambar CR and Seligman PA (1986) Effects of different transferrin forms on transferrin receptor expression, iron uptake and cellular proliferation of human leukemic HL60 cells: mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J Clin Invest 78:1538-1546.
8. Chitambar CR and Wereley JP (1997) Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production. J Biol Chem 272:12151-12157.
9. Chitambar CR and Wereley JP (1998) Transferrin receptor-dependent and -independent iron transport in gallium-resistant human lymphoid leukemic cells. Blood 91:4686-4693.
10. Chitambar CR, Wereley JP, and Matsuyama S (2006) Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition. Mol Cancer Ther 5:2834-2843.
11. Chitambar CR, Zahir SA, Ritch PS, and Anderson T (1997) Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. Am J Clin Oncol 20:173-178.
12. Chitambar CR and Zivkovic Z (1987) Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin- independent mechanisms. Cancer Res 47:3929-3934.
13. Chua MS, Bernstein LR, Li R, and So SK (2006) Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res 26:1739-1743.
14. Collery P, Keppler B, Madoulet C, and Desoize B (2002) Gallium in cancer treatment. Crit Rev Oncol Hematol 42:283-296.
15. Davies NP, Rahmanto YS, Chitambar CR, and Richardson DR (2006) Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates. J Pharmacol Exp Ther 317:153-162.
16. Dhanasekaran A, Kotamraju S, Kalivendi SV, Matsunaga T, Shang T, Keszler A, Joseph J, and Kalyanaraman B (2004) Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem 279:37575- 37587.
17. Einhorn L (2003) Gallium nitrate in the treatment of bladder cancer. Semin Oncol 30:34-41.
18. Green DR and Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626-629.
19. Harris WR and Pecoraro VL (1983) Thermodynamic binding constants for gallium transferrin. Biochemistry 22:292-299.
20. Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
21. Keller J, Bartolucci A, Carpenter JT Jr, and Feagler J (1986) Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a Southeastern Cancer Study Group trial. Cancer Treat Rep 70:1221-1223.
22. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, and Murphy MP (2001) Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 276:4588-4596.
23. Larson SM, Rasey JS, Allen DR, Nelson NJ, Grunbaum Z, Harp GD, and Williams DL (1980) Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst 64:41-53.
24. Little JB, Nagasawa H, Keng PC, Yu Y, and Li CY (1995) Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. J Biol Chem 270:11033-11036.
25. Lubec G (1996) The hydroxyl radical: From chemistry to human disease. J Invest Med 44:324-346.
26. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immmunol Methods 65:55-63.
27. Pro B, Bociek RG, Chitambar CR, Gregory SA, Leonard JP, Smith S, and Novick S (2004) Phase 2 multicenter trial of gallium nitrate in patients with advanced non-Hodgkin's lymphoma (NHL). Blood 104:682A.
28. Raha S and Robinson BH (2000) Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem Sci 25:502-508.
29. Rasey JS, Nelson NJ, and Larson SM (1982) Tumor cell toxicity of stable gallium nitrate: enhancement by transferrin and protection by iron. Eur J Cancer Clin Oncol l8:66l-668.
30. Richardson DR, Tran EH, and Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295-4306.
31. Said Ahmed M, Hung WY, Zu JS, Hockberger P, and Siddique T (2000) Increased reactive oxygen species in familial amyotrophic lateral sclerosis with mutations in SOD1. J Neurol Sci 176:88-94.
32. Taetle R, Castognola J, and Mendelsohn J (1986) Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res 46:1759-1763.
33. Thompson KH, Barta CA, and Orvig C (2006) Metal complexes of maltol and close analogues in medicinal inorganic chemistry. Chem Soc Rev 35:545-556.
34. Trowbridge IS and Lopez F (1982) Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci U S A 79:1175-1179.
35. Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally M, et al. (2006) Four human t(11;14)(q13;q32)- containing cell lines having classic and variant features of mantle cell lymphoma. Leuk Res 30:449-457.
36. Warrell RP, Jr., Coonley CJ, Straus DJ, and Young CW (1983) Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 51:1982-1987.
37. Weick JK, Stephens RL, Baker LH, and Jones SE (1983) Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study. Cancer Treat Rep 67:823-825.
38. Xia F, Wang X, Wang YH, Tsang NM, Yandell DW, Kelsey KT, and Liber HL (1995) Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 55:12-15.
39. Yang M, Kroft SH, and Chitambar CR (2007) Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Mol Cancer Ther 6:633-643.
40. Zimmermann KC, Bonzon C, and Green DR (2001) The machinery of programmed cell death. Pharmacol Ther 92:57-70.